A Phase 1/2, Open-label, Multi-center Study to Assess the Safety and Tolerability of Durvalumab (Anti-PDL1 Antibody) as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocitic Leukemia

Trial Profile

A Phase 1/2, Open-label, Multi-center Study to Assess the Safety and Tolerability of Durvalumab (Anti-PDL1 Antibody) as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocitic Leukemia

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Mar 2018

At a glance

  • Drugs Durvalumab (Primary) ; Bendamustine; Ibrutinib; Lenalidomide; Rituximab
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia; Lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms FUSION NHL 001
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 02 Mar 2018 Planned End Date changed from 6 Jun 2024 to 8 Jul 2022.
    • 02 Mar 2018 Planned primary completion date changed from 6 Jun 2024 to 8 Jul 2022.
    • 02 Mar 2018 Status changed from suspended to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top